TY - JOUR AU - Robertson, J. F. AU - Nicholson, R. I. AU - Bundred, N. J. AU - Anderson, E. AU - Rayter, Z. AU - Dowsett, M. AU - Fox, J. N. AU - Gee, J. M. AU - Webster, A. AU - Wakeling, A. E. AU - Morris, C. AU - Dixon, M. PY - 2001 DA - 2001// TI - Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer JO - Cancer Res VL - 61 ID - Robertson2001 ER - TY - JOUR AU - Dowsett, M. AU - Nicholson, R. I. AU - Pietras, R. J. PY - 2005 DA - 2005// TI - Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance JO - Breast Cancer Res Treat VL - 93 UR - https://doi.org/10.1007/s10549-005-9037-3 DO - 10.1007/s10549-005-9037-3 ID - Dowsett2005 ER - TY - JOUR AU - DeFriend, D. J. AU - Howell, A. AU - Nicholson, R. I. AU - Anderson, E. AU - Dowsett, M. AU - Mansel, R. E. AU - Blamey, R. W. AU - Bundred, N. J. AU - Robertson, J. F. AU - Saunders, C. AU - Baum, H. AU - Walton, P. AU - Sutcliffe, F. A. AU - Wakeling, A. E. PY - 1994 DA - 1994// TI - Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer JO - Cancer Res VL - 54 ID - DeFriend1994 ER - TY - JOUR AU - Gradishar, W. PY - 2005 DA - 2005// TI - Fulvestrant in the treatment of postmenopausal women with advanced breast cancer JO - Expert Rev Anticancer Ther VL - 5 UR - https://doi.org/10.1586/14737140.5.3.445 DO - 10.1586/14737140.5.3.445 ID - Gradishar2005 ER - TY - JOUR AU - Howell, A. AU - Robertson, J. F. AU - Quaresma Albano, J. AU - Aschermannova, A. AU - Mauriac, L. AU - Kleeberg, U. R. AU - Vergote, I. AU - Erikstein, B. AU - Webster, A. AU - Morris, C. PY - 2002 DA - 2002// TI - Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.10.057 DO - 10.1200/JCO.2002.10.057 ID - Howell2002 ER - TY - JOUR AU - Osborne, C. K. AU - Pippen, J. AU - Jones, S. E. AU - Parker, L. M. AU - Ellis, M. AU - Come, S. AU - Gertler, S. Z. AU - May, J. T. AU - Burton, G. AU - Dimery, I. AU - Webster, A. AU - Morris, C. AU - Elledge, R. AU - Buzdar, A. PY - 2002 DA - 2002// TI - Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.10.058 DO - 10.1200/JCO.2002.10.058 ID - Osborne2002 ER - TY - JOUR AU - Robertson, J. F. AU - Osborne, C. K. AU - Howell, A. AU - Jones, S. E. AU - Mauriac, L. AU - Ellis, M. AU - Kleeberg, U. R. AU - Come, S. E. AU - Vergote, I. AU - Gertler, S. AU - Buzdar, A. AU - Webster, A. AU - Morris, C. PY - 2003 DA - 2003// TI - Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials JO - Cancer VL - 98 UR - https://doi.org/10.1002/cncr.11468 DO - 10.1002/cncr.11468 ID - Robertson2003 ER - TY - JOUR AU - Robertson, J. F. PY - 2007 DA - 2007// TI - Fulvestrant (Faslodex) - how to make a good drug better JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-7-774 DO - 10.1634/theoncologist.12-7-774 ID - Robertson2007 ER - TY - JOUR AU - Kuter, I. AU - Gee, J. M. AU - Hegg, R. AU - Singer, C. F. AU - Badwe, R. A. AU - Lowe, E. S. AU - Emeribe, U. A. AU - Anderson, E. AU - Sapunar, F. AU - Finlay, P. AU - Nicholson, R. I. AU - Bines, J. AU - Harbeck, N. PY - 2012 DA - 2012// TI - Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-011-1947-7 DO - 10.1007/s10549-011-1947-7 ID - Kuter2012 ER - TY - JOUR AU - Di Leo, A. AU - Jerusalem, G. AU - Petruzelka, L. AU - Torres, R. AU - Bondarenko, I. N. AU - Khasanov, R. AU - Verhoeven, D. AU - Pedrini, J. L. AU - Smirnova, I. AU - Lichinitser, M. R. AU - Pendergrass, K. AU - Garnett, S. AU - Lindemann, J. P. AU - Sapunar, F. AU - Martin, M. PY - 2010 DA - 2010// TI - Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.8415 DO - 10.1200/JCO.2010.28.8415 ID - Di Leo2010 ER - TY - JOUR AU - Bergh, J. AU - Jönsson, P. E. AU - Lidbrink, E. K. AU - Trudeau, M. AU - Eiermann, W. AU - Brattström, D. AU - Lindemann, J. P. AU - Wiklund, F. AU - Henriksson, R. PY - 2012 DA - 2012// TI - FACT: an open-label randomized Phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.1095 DO - 10.1200/JCO.2011.38.1095 ID - Bergh2012 ER - TY - JOUR AU - Mehta, R. S. AU - Barlow, W. E. AU - Albain, K. S. AU - Vandenberg, T. A. AU - Dakhil, S. R. AU - Tirumali, N. R. AU - Lew, D. L. AU - Hayes, D. F. AU - Gralow, J. R. AU - Livingston, R. B. AU - Hortobagyi, G. N. PY - 2012 DA - 2012// TI - Combination anastrozole and fulvestrant in metastatic breast cancer JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1201622 DO - 10.1056/NEJMoa1201622 ID - Mehta2012 ER - TY - JOUR AU - Robertson, J. F. R. AU - Llombart, A. AU - Rolski, J. AU - Feltl, D. AU - Dewar, J. AU - Macpherson, E. AU - Lindemann, J. AU - Ellis, M. J. PY - 2009 DA - 2009// TI - Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.1136 DO - 10.1200/JCO.2008.21.1136 ID - Robertson2009 ER - TY - JOUR AU - Smith, I. E. AU - Dowsett, M. AU - Ebbs, S. R. AU - Dixon, J. M. AU - Skene, A. AU - Blohmer, J. U. AU - Ashley, S. E. AU - Francis, S. AU - Boeddinghaus, I. AU - Walsh, G. PY - 2005 DA - 2005// TI - Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.005 DO - 10.1200/JCO.2005.04.005 ID - Smith2005 ER - TY - JOUR AU - Mouridsen, H. T. PY - 2007 DA - 2007// TI - Letrozole in advanced breast cancer: the PO25 trial JO - Breast Cancer Res Treat VL - 105 UR - https://doi.org/10.1007/s10549-007-9527-6 DO - 10.1007/s10549-007-9527-6 ID - Mouridsen2007 ER - TY - JOUR AU - Ellis, M. J. AU - Suman, V. J. AU - Hoog, J. AU - Lin, L. AU - Snider, J. AU - Prat, A. AU - Parker, J. S. AU - Luo, J. AU - Deschryver, K. AU - Allred, D. C. AU - Esserman, L. J. AU - Unzeitig, G. W. AU - Margenthaler, J. AU - Babiera, G. V. AU - Marcom, P. K. AU - Guenther, J. M. AU - Watson, M. A. AU - Leitch, M. AU - Hunt, K. AU - Olson, J. A. PY - 2011 DA - 2011// TI - Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031 JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.31.6950 DO - 10.1200/JCO.2010.31.6950 ID - Ellis2011 ER - TY - JOUR AU - Macedo, L. AU - Sabnis, G. AU - Goloubeva, O. AU - Brodie, A. PY - 2008 DA - 2008// TI - Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-6807 DO - 10.1158/0008-5472.CAN-07-6807 ID - Macedo2008 ER - TY - JOUR AU - Johnston, S. AU - Kilburn, L. S. AU - Ellis, P. AU - Cameron, D. AU - Dodwell, D. AU - Howell, A. AU - Im, Y. H. AU - Coombes, G. AU - Dowsett, M. AU - Bliss, J. M. PY - 2012 DA - 2012// TI - Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor - first results of the SoFEa trial JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/S0959-8049(12)70687-1 DO - 10.1016/S0959-8049(12)70687-1 ID - Johnston2012 ER - TY - BOOK AU - Robertson, J. F. R. AU - Lindemann, J. AU - Llombart-Cussac, A. AU - Rolski, J. AU - Feltl, D. AU - Dewar, J. AU - Emerson, L. AU - Dean, A. AU - Ellis, M. J. PY - 2010 DA - 2010// TI - A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study ID - Robertson2010 ER - TY - JOUR AU - Shou, J. AU - Massarweh, S. AU - Osborne, C. K. AU - Wakeling, A. E. AU - Ali, S. AU - Weiss, H. AU - Schiff, R. PY - 2004 DA - 2004// TI - Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh166 DO - 10.1093/jnci/djh166 ID - Shou2004 ER - TY - JOUR AU - Martin, L. A. AU - Farmer, I. AU - Johnston, S. R. AU - Ali, S. AU - Dowsett, M. PY - 2005 DA - 2005// TI - Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation JO - Endocr Relat Cancer VL - 12 UR - https://doi.org/10.1677/erc.1.01023 DO - 10.1677/erc.1.01023 ID - Martin2005 ER - TY - JOUR AU - Staka, C. M. AU - Nicholson, R. I. AU - Gee, J. M. PY - 2005 DA - 2005// TI - Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model JO - Endocr Relat Cancer VL - 12 UR - https://doi.org/10.1677/erc.1.01006 DO - 10.1677/erc.1.01006 ID - Staka2005 ER - TY - JOUR AU - Britton, D. J. AU - Hutcheson, I. R. AU - Knowlden, J. M. AU - Barrow, D. AU - Giles, M. AU - McClelland, R. A. AU - Gee, J. M. AU - Nicholson, R. I. PY - 2006 DA - 2006// TI - Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth JO - Breast Cancer Res Treat VL - 96 UR - https://doi.org/10.1007/s10549-005-9070-2 DO - 10.1007/s10549-005-9070-2 ID - Britton2006 ER - TY - BOOK AU - Kuter, I. AU - Sapunar, F. AU - McCormack, P. PY - 2008 DA - 2008// TI - Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: results from the NEWEST study ID - Kuter2008 ER - TY - JOUR AU - Rose, C. AU - Kamby, C. AU - Mouridsen, H. T. AU - Bastholt, L. AU - Brincker, H. AU - Skovgaard-Poulsen, H. AU - Andersen, A. P. AU - Loft, H. AU - Dombernowsky, P. AU - Andersen, K. W. PY - 1986 DA - 1986// TI - Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone JO - Breast Cancer Res Treat VL - 7 ID - Rose1986 ER - TY - JOUR AU - Ingle, J. N. AU - Green, S. J. AU - Ahmann, D. L. AU - Long, H. J. AU - Edmonson, J. H. AU - Rubin, J. AU - Chang, M. N. AU - Creagan, E. T. PY - 1986 DA - 1986// TI - Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer JO - J Clin Oncol VL - 4 ID - Ingle1986 ER - TY - JOUR AU - Baum, M. AU - Budzar, A. U. AU - Cuzick, J. AU - Forbes, J. AU - Houghton, J. H. AU - Klijn, J. G. AU - Sahmoud, T. PY - 2002 DA - 2002// TI - Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial JO - Lancet VL - 359 UR - https://doi.org/10.1016/S0140-6736(02)09088-8 DO - 10.1016/S0140-6736(02)09088-8 ID - Baum2002 ER -